A Journey of Hope: Norman Ng’s Inspiring Story

In this episode of OncoInfluencers on OncoDaily, Jemma Arakelyan interviews Norman Ng, a lung cancer survivor and Director of Patient Advocacy at Healthcare Thinkers. Norman shares his personal journey with stage 4 lung cancer, his work founding the Lung Cancer Patient Concern Group, and his role in bringing ALK inhibitors to Hong Kong. He also discusses the importance of early detection, patient advocacy, and offers advice for newly diagnosed patients. This inspiring conversation highlights Norman’s resilience and dedication to improving patient care.

Dr. Jemma Arakelyan is a medical oncologist and the Chief Executive Officer of The Institute of Cancer and Crisis. Under her leadership, the Institute is dedicated to raising awareness and providing support for cancer patients facing critical challenges, including those arising from war and pandemics.

Currently, she is pursuing her Ph.D. at the City University of Hong Kong, focusing on the development of new anticancer treatments and the mechanisms driving cancer progression. In addition to her academic work, Dr. Arakelyan is actively involved in several scientific organizations, including the European School of Oncology (ESO), the European Society of Medical Oncology (ESMO), and the American Society of Clinical Oncology (ASCO).

She also serves as an advisor at the Immune Oncology Research Institute, where they work closely on the clinical development of novel immunotherapeutic agents.

In 2012, Norman Ng was a pivotal figure in the fight against cancer in Hong Kong. As the head of Pfizer’s oncology products, he introduced the first-generation ALK inhibitor, Crizotinib, a groundbreaking treatment that opened new doors for lung cancer patients. Little did he know that years later, he would face his own battle with stage 4 ALK-positive lung cancer.

Despite the challenges ahead, Norman has transformed his personal journey into a powerful advocacy mission. Currently serving as the Director of Patient Advocacy and Public Affairs for Healthcare Thinkers, he works tirelessly to represent patient interests and build relationships with stakeholders. His commitment extends to engaging healthcare providers, developing public affairs strategies, and advocating for patient rights, ensuring that the voices of those affected by cancer are heard loud and clear.

In December 2023, Norman took on the role of Convener for the Lung Cancer Patient Concern Group. This initiative aims to support patients navigating their diagnoses, advocate for comprehensive care, and raise public awareness about lung cancer. Through his leadership, the group strives to create a community where patients can find hope and support.

Previously, as External Affairs Director at HUTCHMED, Norman formulated lobbying strategies that successfully led to the approval of innovative drugs, including the first-ever innovative drug registered in Hong Kong under the new mechanism. His extensive experience in external affairs has positioned him as a key figure in shaping healthcare policies and improving access to life-saving treatments.

Norman’s impressive career spans several reputable organizations, including Merck Sharp and Dohme and GlaxoSmithKline, where he played critical roles in advancing public health initiatives and patient engagement. His passion for healthcare is evident in his numerous accolades, including the Pfizer Upjohn Award, which recognized his drive for innovation in immunization programs.

With a Master’s in Medical Biochemistry and a wealth of experience, Norman has dedicated his life to enhancing patient care and treatment access. Now, as he faces his own diagnosis, he remains a voice of hope for others battling cancer, collaborating with OncoDaily—a platform that amplifies the stories and struggles of oncological patients in Hong Kong.

In this chapter of his life, Norman Ng is not just a patient; he is an advocate, a mentor, and a beacon of hope for many. His journey illustrates the resilience of the human spirit and the power of community, reminding us all that even in the face of adversity, there is strength in unity and hope in advocacy.